KIORA PHARMACEUTICALS INC has raised $20.0M in total funding. The most recent round was Series D.
KIORA PHARMACEUTICALS INC is headquartered in Encinitas, CA.
Vision-threatening retinal diseases include conditions with limited or no effective therapies available today.
Kiora develops small-molecule therapies, including pipeline candidates KIO-301 and KIO-104, targeting pathways underlying retinal disease to slow, stop, or restore vision loss.
Kiora Pharmaceuticals is a publicly traded, clinical-stage biopharmaceutical company (Nasdaq: KPRX) developing treatments for retinal disease, led by CEO Brian Strem.
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.